Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

A woman carrying a baby argues with the police as she takes part in an anti-vaccination protest outside the Science museum on September 3, 2021 in London, England. The anti-vaccination protesters have gathered in London following the Medicines and Healthcare products Regulatory Agency’s decision to approve the Pfizer COVID-19 vaccine for use on children between the ages of 12 and 15. This afternoon it was announced that the Joint Committee on Vaccination and Immunisation (JCVI) will not recommend the mass vaccination of children in the UK.

Chris Ratcliffe/Getty Images

A committee of scientists that advises the British government on immunization has held back on recommending COVID-19 vaccinations for healthy children between the ages of 12 and 15 partly because of uncertainty surrounding the safety of the shot.

The Joint Committee on Vaccination and Immunisation (JCVI) said Friday that while the health benefits of inoculating children were marginally greater than the risks, “the margin of benefit is considered too small to support universal vaccination of healthy 12- to 15-year-olds at this time.” However, the committee said the government should consider views from other health experts “on the wider societal and educational impacts” of vaccination.

Adam Finn, a professor of pediatrics at the University of Bristol who is on the JCVI, said there were “significant uncertainties around the safety of the vaccine that have not yet been clarified.” He said there has been evidence of a link between mRNA vaccines – such as the Pfizer-BioNTech shot – and myocarditis, which is a form of heart inflammation.

Story continues below advertisement

“This is rare and individuals who experience it usually get better quite quickly,” Dr. Finn told a media briefing on Friday. “The uncertainly relates to the longer-term consequences. Our pediatric cardiology colleagues from North America, as well as in this country, are advising us that there is significant uncertainty around that.” He said JCVI scientists were waiting to see the results of further studies.

Unlike Canada and many European countries, Britain has not vaccinated healthy children under the age of 16. The British government has been eager to launch a vaccination program, especially since most children returned to school last week, but officials had been waiting for the JCVI’s advice. The government said it will now consult with chief medical officers of health in England, Scotland, Wales and Northern Ireland before making a final decision. “We will consider the advice, building on the advice from the JCVI, before making a decision shortly,” Health Secretary Sajid Javid said Friday.

The JCVI has recommended vaccination for children with underlying health issues, such as heart conditions and Type 1 diabetes. But the committee has said that since healthy children rarely become severely ill from COVID-19, the benefits of vaccination were limited.

“For otherwise healthy 12- to 15-year-old children, their risk of severe COVID-19 disease is small and therefore the potential for benefit from [vaccination] is also small,” said Wei Shen Lim, chair of the COVID-19 immunization group at the JCVI.

Anthony Harnden, deputy chair of the JCVI, said studies have shown that there are between three and 17 cases of myocarditis in children for every one million doses of vaccine. “That’s a very wide range because the data is uncertain,” he said. “This was a very finely balanced decision but definitely whilst the benefits slightly outweigh the risks, the risks are very uncertain at the moment.”

Dr. Harnden acknowledged that it was unusual for the JCVI to urge the government to consider other views. However, he said the impact of the pandemic on education was important and beyond the scope of the committee. “It’s us as a committee feeling that we don’t have the expertise to assess the educational aspect,” he said.

Dr. Finn said the JCVI has also been concerned about children developing “long COVID” – when coronavirus symptoms appear to last for months or longer. Long COVID “is part of our consideration and we’re keeping an eye on the evidence as it comes through,” he said.

Story continues below advertisement

A recent study in Britain estimated that up to one in seven teenagers who catch COVID-19 still had related symptoms three months after becoming ill. Researchers said that was lower than many other estimates, which put the figure as high as 50 per cent, but still concerning given that it would translate into roughly 30,000 teenagers in the U.K. However, they added that it wasn’t clear whether vaccination would prevent long-lasting symptoms.

Dr. Finn also said it was not unusual that Britain had taken a different approach to vaccinating children. “I don’t think anyone should be that surprised that things don’t always come out the same at different times in different countries,” he said. He noted that vaccine rollout programs had varied widely along with research activity. “The idea that somehow everyone would be in lockstep on this is quite misguided.”

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies